Who Generates Higher Gross Profit? BioMarin Pharmaceutical Inc. or Perrigo Company plc

Perrigo leads BioMarin in gross profit over a decade.

__timestampBioMarin Pharmaceutical Inc.Perrigo Company plc
Wednesday, January 1, 20146212760001447700000
Thursday, January 1, 20157378870001712400000
Friday, January 1, 20169072340002051800000
Sunday, January 1, 201710718600001979500000
Monday, January 1, 201811759480001831500000
Tuesday, January 1, 201913445820001773300000
Wednesday, January 1, 202013361830001815200000
Friday, January 1, 202113757600001416200000
Saturday, January 1, 202216123700001455400000
Sunday, January 1, 202318421610001680400000
Monday, January 1, 20242273680000
Loading chart...

Infusing magic into the data realm

BioMarin vs. Perrigo: A Decade of Gross Profit Trends

In the competitive landscape of pharmaceuticals, understanding who leads in profitability can offer valuable insights. Over the past decade, from 2014 to 2023, Perrigo Company plc consistently outperformed BioMarin Pharmaceutical Inc. in terms of gross profit. Perrigo's gross profit peaked in 2016, reaching nearly 2.1 billion, while BioMarin's highest was in 2023, with approximately 1.8 billion. Despite BioMarin's impressive growth, increasing its gross profit by nearly 200% from 2014 to 2023, Perrigo maintained a steady lead, averaging around 1.7 billion annually. This trend highlights Perrigo's robust market position and operational efficiency. However, BioMarin's upward trajectory suggests a promising future, potentially closing the gap. As the pharmaceutical industry evolves, these financial metrics provide a glimpse into the strategic maneuvers of these two giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025